Industry Expert Sessions

Industry Expert Sessions provide exhibiting companies the opportunity to present new research findings on products, detail products, conduct demonstrations and highlight new products.

These sessions are solely promotional, and are not eligible for continuing medical education credit. They will all take place in the Moscone West Exhibit Hall.

Saturday

11 to 11:45 a.m.: “CAPS: A Family of Rare Genetic Diseases — Could You Be Missing the Diagnosis?”

This presentation will provide information on the clinical features, diagnosis, and pathophysiology of CAPS. It will give participants the ability to recognize the characteristic urticaria-like rash of CAPS, along with other diagnostic features. The presentation will also explain the IL-1β cytokine-driven pathogenesis of CAPS, and how to manage CAPS with an IL-1β blocker. Hosted by Novartis

12:15 to 1 p.m.: “An Oral PDE4 Inhibitor for Plaque Psoriasis”

Hosted by Celgene Corporation

1:30 to 2:15 p.m.: “Treatment of Symptomatic Chronic Idiopathic Urticaria Despite H1 Antihistamines”

Genentech and Novartis will be hosting a non-CME product theater program on the “Treatment of Symptomatic Chronic Idiopathic Urticaria Despite H1 Antihistamines”. This program will be presented by Dr. Don A. Bukstein of the Allergy, Asthma and Sinus Center in Greenfield, WI and Dr. Howard Sofen of UCLA and Dermatology Research Associates in Los Angeles. Hosted by Genentech/Novartis

 

Sunday

11 to 11:45 a.m.: “Addressing the Visible Signs of Aging and Sun-Damaged Skin: Topical Skin Care and Laser Treatment”

Hosted by Obagi Medical Products, a division of Valeant Pharmaceuticals, Inc.

12:15 to 1 p.m.: “Trending Topics in Plaque Psoriasis”

Hot topics in psoriasis, including the role of the IL-17 pathway in plaque psoriasis, shifting the focus back on the patient, and re-evaluating treatment goals. Hosted by Amgen

1:30 to 2:15 p.m.: “Perspectives in the Management of Early Stage (IA and IB) MF”CTCL: Current Concepts in Clinical Practice”

The management of early stage mycosis fungoides”type cutaneous T”cell lymphoma (MF”CTCL) has provided challenges for the clinician. During this program, an expert will explore the changing dynamics in diagnosis and management of early stage MF”CTCL, and what these changes mean for clinical practice. Hosted by Actelion Pharamceuticals US, Inc.

Return to index

Top